Aptevo Therapeutics Inc. (APVO)
4.49
-0.06 (-1.32%)
At close: Jan 15, 2025, 1:43 PM
undefined% (undefined)
| Bid | 4.49 |
| Market Cap | 6.55M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -415.99 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.55 |
| Volume | 30,879 |
| Avg. Volume (20D) | 346,247 |
| Open | 4.60 |
| Previous Close | 4.55 |
| Day's Range | 4.32 - 4.60 |
| 52-Week Range | 3.65 - 399.60 |
| Beta | undefined |
About APVO
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational ...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 20, 2016
Employees 40
Stock Exchange NASDAQ
Ticker Symbol APVO
Analyst Forecast
According to 1 analyst ratings, the average rating for APVO stock is "Buy." The 12-month stock price forecast is $296, which is an increase of 6492.57% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago ·
Source
Aptevo Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
2 months ago ·
Source
+19.69%
Aptevo Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS results.
